HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives

Valentina Fanotto, Elena Ongaro, Karim Rihawi, Antonio Avallone, Nicola Silvestris, L. Fornaro, E. Vasile, L. Antonuzzo, Francesco Leone, G. Rosati, Francesco Giuliani, Roberto Bordonaro, Mario Scartozzi, Giovanna De maglio, Francesca V. Negri, Gianpiero Fasola, Giuseppe Aprile

Research output: Contribution to journalReview article

Abstract

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

Original languageEnglish
Pages (from-to)69060-69074
Number of pages15
JournalOncotarget
Volume7
Issue number42
Publication statusPublished - Aug 12 2016

Fingerprint

Stomach Neoplasms
Colorectal Neoplasms
Neoplasms
Stomach
Adenocarcinoma
Breast Neoplasms
Inhibition (Psychology)
Therapeutics

Keywords

  • Colorectal cancer
  • Gastric cancer
  • HER2-inhibition
  • Predictive factor
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

Fanotto, V., Ongaro, E., Rihawi, K., Avallone, A., Silvestris, N., Fornaro, L., ... Aprile, G. (2016). HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget, 7(42), 69060-69074.

HER-2 inhibition in gastric and colorectal cancers : Tangible achievements, novel acquisitions and future perspectives. / Fanotto, Valentina; Ongaro, Elena; Rihawi, Karim; Avallone, Antonio; Silvestris, Nicola; Fornaro, L.; Vasile, E.; Antonuzzo, L.; Leone, Francesco; Rosati, G.; Giuliani, Francesco; Bordonaro, Roberto; Scartozzi, Mario; De maglio, Giovanna; Negri, Francesca V.; Fasola, Gianpiero; Aprile, Giuseppe.

In: Oncotarget, Vol. 7, No. 42, 12.08.2016, p. 69060-69074.

Research output: Contribution to journalReview article

Fanotto, V, Ongaro, E, Rihawi, K, Avallone, A, Silvestris, N, Fornaro, L, Vasile, E, Antonuzzo, L, Leone, F, Rosati, G, Giuliani, F, Bordonaro, R, Scartozzi, M, De maglio, G, Negri, FV, Fasola, G & Aprile, G 2016, 'HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives', Oncotarget, vol. 7, no. 42, pp. 69060-69074.
Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L et al. HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget. 2016 Aug 12;7(42):69060-69074.
Fanotto, Valentina ; Ongaro, Elena ; Rihawi, Karim ; Avallone, Antonio ; Silvestris, Nicola ; Fornaro, L. ; Vasile, E. ; Antonuzzo, L. ; Leone, Francesco ; Rosati, G. ; Giuliani, Francesco ; Bordonaro, Roberto ; Scartozzi, Mario ; De maglio, Giovanna ; Negri, Francesca V. ; Fasola, Gianpiero ; Aprile, Giuseppe. / HER-2 inhibition in gastric and colorectal cancers : Tangible achievements, novel acquisitions and future perspectives. In: Oncotarget. 2016 ; Vol. 7, No. 42. pp. 69060-69074.
@article{42c2ad3b44474c668b96e665c5adb414,
title = "HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives",
abstract = "HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.",
keywords = "Colorectal cancer, Gastric cancer, HER2-inhibition, Predictive factor, Prognosis",
author = "Valentina Fanotto and Elena Ongaro and Karim Rihawi and Antonio Avallone and Nicola Silvestris and L. Fornaro and E. Vasile and L. Antonuzzo and Francesco Leone and G. Rosati and Francesco Giuliani and Roberto Bordonaro and Mario Scartozzi and {De maglio}, Giovanna and Negri, {Francesca V.} and Gianpiero Fasola and Giuseppe Aprile",
year = "2016",
month = "8",
day = "12",
language = "English",
volume = "7",
pages = "69060--69074",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "42",

}

TY - JOUR

T1 - HER-2 inhibition in gastric and colorectal cancers

T2 - Tangible achievements, novel acquisitions and future perspectives

AU - Fanotto, Valentina

AU - Ongaro, Elena

AU - Rihawi, Karim

AU - Avallone, Antonio

AU - Silvestris, Nicola

AU - Fornaro, L.

AU - Vasile, E.

AU - Antonuzzo, L.

AU - Leone, Francesco

AU - Rosati, G.

AU - Giuliani, Francesco

AU - Bordonaro, Roberto

AU - Scartozzi, Mario

AU - De maglio, Giovanna

AU - Negri, Francesca V.

AU - Fasola, Gianpiero

AU - Aprile, Giuseppe

PY - 2016/8/12

Y1 - 2016/8/12

N2 - HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

AB - HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

KW - Colorectal cancer

KW - Gastric cancer

KW - HER2-inhibition

KW - Predictive factor

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84995403741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995403741&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 69060

EP - 69074

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 42

ER -